Sleep Apnea in Elderly

VA Office of Research and Development

Status and phase: Enrolling; Phase 4

Conditions: Sleep Apnea; Elderly Adults

Treatments: Other: Hyperoxia/oxygen; Drug: Finasteride; Drug: Acetazolamide

Study type: Interventional

Funder types: Other U.S. Federal agency

Identifiers

NCT02703220

PULM-008-14F

Details and patient eligibility

About

Sleep-disordered breathing (SDB or sleep apnea) is very common among elderly Veterans and leads to increased morbidity and mortality in this population. The proposal aims to identity whether oxygen, finasteride and acetazolamide can be effective in reducing unstable breathing and eliminating sleep apnea in the elderly via different mechanisms. This proposal will enhance the investigators' understanding of the pathways that contribute to the development of sleep apnea in the elderly. The investigators expect that the results obtained from this study will positively impact the health of Veterans by identifying new treatment modalities for sleep apnea. A cumulative effect of the investigators' research will fulfill the long-term goal of improving the quality of life of elderly Veterans suffering from sleep apnea and its potential life-threatening complications.

Full description

Sleep apnea-hypopnea syndrome (SAHS) has a high prevalence and is associated with adverse cardiovascular consequences in elderly Veterans. Positive airway pressure therapy is deemed cumbersome and often associated with non-adherence to therapy. This proposal will investigate whether alternative therapies can be developed by modulating specific physiologic mechanisms of ventilatory control. Specifically, the investigators will study whether interventions with sustained hyperoxia (Aim 1), finasteride (Aim 2) and acetazolamide (Aim 3) will reduce breathing instability during sleep by reducing chemoresponsiveness and/or increasing cerebrovascular reactivity (CVR) in order to alleviate sleep disordered breathing in the elderly with sleep apnea. The proposed aims will also allow us to delineate key mechanisms of breathing instability in the elderly. The investigators envision that the results obtained from this project will ultimately allow us to develop novel alternative therapies for sleep apnea in the elderly. We will also compare CVR in young vs older adults

Enrollment: 100 estimated patients

Sex: All

Ages: 60 to 89 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adults who are 60 years old and older, with mild to moderate sleep apnea with AHI >/=5 to 20/hr with central, obstructive, mixed apneas and hypopneas.
• For the finasteride protocol elderly men with above criteria will be enrolled.

Exclusion criteria

• Patients with severe sleep apnea (AHI>20/hr)

• Patients with history of prostate cancer

• Males with hypogonadism

• History of cardiac disease, including myocardial infarction

• Bypass surgery

• Atrial and ventricular tachy-bradycardias

• Systolic congestive heart failure and Cheyne-Stokes respiration

• Current unstable angina

• Stroke

• Schizophrenia

• Untreated hypothyroidism

• Seizure disorder

• Preexisting renal failure and liver disorders

• Failure to give informed consent.

• Patients with significant pulmonary diseases by history and abnormal pulmonary function testing, including moderate obstructive/restrictive lung/chest wall disorders with resting oxygen saturation of <96% or on supplemental oxygen

• Patients on certain medications including:

  • study drugs
  • sympathomimetics/parasympathomimetics or their respective blockers
  • narcotics
  • antidepressants
  • anti-psychotic agents
  • other central nervous system (CNS) altering medications
  • current alcohol, tobacco or recreational drug use

• Patients with BMI>34kg/m2 will be excluded to avoid the effects of morbid obesity on pulmonary mechanics and ventilatory control

• Elderly with unstable gait or mobility issues that may preclude safe participation

• Individuals with allergy to finasteride or acetazolamide will be excluded from the specific protocol

• Pregnant women

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

100 participants in 3 patient groups

Hyperoxia

Experimental group

Description:

Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during (non-rapid eye movement sleep) NREM sleep.

Treatment:

Other: Hyperoxia/oxygen

Acetazolamide (ACZ)

Experimental group

Description:

Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 7 days prior to the experimental night, on the night of the study and the subsequent night when polysomnography (PSG) will be performed.

Treatment:

Drug: Acetazolamide

Finasteride

Experimental group

Description:

Determine the effect of oral finasteride therapy vs placebo for 1 month on SDB and the AT and chemosensitivity during NREM sleep.

Treatment:

Drug: Finasteride